STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Enliven Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Enliven Therapeutics (ELVN) disclosed insider transactions by its Chief Operating Officer. On 11/07/2025, the reporting person executed sales of 6,054 shares at a weighted average price of $17.3503 and 613 shares at a weighted average price of $17.9371, effected under a Rule 10b5-1 trading plan adopted on September 30, 2024.

The trades were completed in multiple transactions within disclosed price ranges, and the shares are held indirectly by The Patel / Dong Family Trust, for which the reporting person serves as trustee. Following the reported sales, beneficial ownership stood at 269,974 shares held indirectly.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Anish

(Last) (First) (Middle)
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD

(Street)
BOULDER CO 80301

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/07/2025 S(1) 6,054 D $17.3503(2) 270,587 I See footnote(3)
Common Stock 11/07/2025 S(1) 613 D $17.9371(4) 269,974 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
2. This transaction was executed in multiple trades at prices ranging from $16.825 to $17.8248. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. The shares are held by The Patel / Dong Family Trust.
4. This transaction was executed in multiple trades at prices ranging from $17.835 to $18.265. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Ben Hohl, by power of attorney 11/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ELVN report?

The COO reported sales of 6,054 shares at a weighted average of $17.3503 and 613 shares at a weighted average of $17.9371 on 11/07/2025.

Were the ELVN sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024.

What are the price ranges for the ELVN trades?

For 6,054 shares: $16.825–$17.8248. For 613 shares: $17.835–$18.265.

How many ELVN shares are beneficially owned after the transactions?

After the reported sales, beneficial ownership is 269,974 shares, held indirectly.

Who holds the ELVN shares reported in the filing?

The shares are held by The Patel / Dong Family Trust, for which the reporting person serves as trustee.

What is the reporting person’s role at ELVN?

The reporting person is the company’s Chief Operating Officer.
Enliven Therapeutics Inc

NASDAQ:ELVN

ELVN Rankings

ELVN Latest News

ELVN Latest SEC Filings

ELVN Stock Data

1.20B
46.24M
8.89%
102.24%
8.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOULDER